Intrinsic biventricular dysfunction in Marfan syndrome

Heart

Volumn 97, Issue 24, 2011, Pages 2063-2068

  De Witte, Piet ^a,b   Aalberts, Jan J J ^c   Radonic, Teodora ^a,b   Timmermans, Janneke ^d   Scholte, Arthur J ^e   Zwinderman, Aeilko H ^a   Mulder, Barbara J M ^a,b   Groenink, Maarten ^a,b   Van Den Berg, Maarten P ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; BIVENTRICULAR DYSFUNCTION; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DISEASE ASSOCIATION; ELASTICITY; FEMALE; HEART CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE DIASTOLIC VOLUME; HEART VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HEART VENTRICLE SYSTOLIC VOLUME; HEART VOLUME; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MARFAN SYNDROME; MYOCARDIAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; AORTA, THORACIC; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ELASTICITY; FEMALE; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MARFAN SYNDROME; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; VENTRICULAR DYSFUNCTION;

EID: 82255162640     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300169     Document Type: Article

References (40)

1. Pyeritz RE, McKusick VA. The Marfan syndrome: diagnosis and management. N Engl J Med 1979;300:772-7. (Pubitemid 9172315)
2. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352:337-9. (Pubitemid 21912353)
3. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407-11. (Pubitemid 36278859)
4. Pyeritz RE. Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart 2009;95:173-5.
5. Urschel CW, Covell JW, Sonnenblick EH, et al. Effects of decreased aortic compliance on performance of the left ventricle. Am J Physiol 1968;214:298-304.
6. Groenink M, de RA, Mulder BJ, et al. Biophysical properties of the normal-sized aorta in patients with Marfan syndrome: evaluation with MR flow mapping. Radiology 2001;219:535-40.
7. Chen CH, Nakayama M, Nevo E, et al. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 1998;32:1221-7.
8. Kass DA. Ventricular arterial stiffening: integrating the pathophysiology. Hypertension 2005;46:185-93. (Pubitemid 40946512)
9. Chatrath R, Beauchesne LM, Connolly HM, et al. Left ventricular function in the Marfan syndrome without significant valvular regurgitation. Am J Cardiol 2003;91:914-16. (Pubitemid 36363751)
10. Das BB, Taylor AL, Yetman AT. Left ventricular diastolic dysfunction in children and young adults with Marfan syndrome. Pediatr Cardiol 2006;27:256-8.
11. De Backer JF, Devos D, Segers P, et al. Primary impairment of left ventricular function in Marfan syndrome. Int J Cardiol 2006;112:353-8. (Pubitemid 44415054)
12. Kiotsekoglou A, Sutherland GR, Moggridge JC, et al. The unravelling of primary myocardial impairment in Marfan syndrome by modern echocardiography. Heart 2009;95:1561-6.
13. Meijboom LJ, Timmermans J, van Tintelen JP, et al. Evaluation of left ventricular dimensions and function in Marfan's syndrome without significant valvular regurgitation. Am J Cardiol 2005;95:795-7. (Pubitemid 40332667)
14. Rybczynski M, Koschyk DH, Aydin MA, et al. Tissue Doppler imaging identifies myocardial dysfunction in adults with Marfan syndrome. Clin Cardiol 2007;30:19-24. (Pubitemid 46147605)
15. Savolainen A, Nisula L, Keto P, et al. Left ventricular function in children with the Marfan syndrome. Eur Heart J 1994;15:625-30. (Pubitemid 24186328)
16. Alpendurada F, Wong J, Kiotsekoglou A, et al. Evidence for Marfan cardiomyopathy. Eur J Heart Fail 2010;12:1085-91.
17. Kiotsekoglou A, Saha SK, Moggridge JC, et al. Effect of aortic stiffness on left ventricular long-axis systolic function in adults with Marfan syndrome. Hellenic J Cardiol 2010;51:501-11.
18. Radonic T, de Witte P, Baars MJ, et al. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials 2010;11:3.
19. De Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-26. (Pubitemid 26131122)
20. Groenink M, de RA, Mulder BJ, et al. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998;82:203-8.
21. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-68. (Pubitemid 46276943)
22. Hudsmith LE, Petersen SE, Francis JM, et al. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 2005;7:775-82. (Pubitemid 41770055)
23. Grotenhuis HB, Westenberg JJ, Steendijk P, et al. Validation and reproducibility of aortic pulse wave velocity as assessed with velocity-encoded MRI. J Magn Reson Imaging 2009;30:521-6.
24. Roman MJ, Devereux RB, Kramer-Fox R, et al. Comparison of cardiovascular and skeletal features of primary mitral valve prolapse and Marfan syndrome. Am J Cardiol 1989;63:317-21. (Pubitemid 19049242)
25. Kiotsekoglou A, Bajpai A, Bijnens BH, et al. Early impairment of left ventricular longaxis systolic function demonstrated by reduced atrioventricular plane displacement in patients with Marfan syndrome. Eur J Echocardiogr 2008;9:605-13.
26. Eichhorn JG, Krissak R, Rudiger HJ, et al. [Compliance of the normal-sized aorta in adolescents with Marfan syndrome: comparison of MR measurements of aortic distensibility and pulse wave velocity] (Article in German). Rofo 2007;179:841-6. (Pubitemid 47253536)
27. Hirata K, Triposkiadis F, Sparks E, et al. The Marfan syndrome: abnormal aortic elastic properties. J Am Coll Cardiol 1991;18:57-63.
28. Jeremy RW, Huang H, Hwa J, et al. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol 1994;74:369-73. (Pubitemid 24253475)
29. Nollen GJ, Meijboom LJ, Groenink M, et al. Comparison of aortic elasticity in patients with the marfan syndrome with and without aortic root replacement. Am J Cardiol 2003;91:637-40. (Pubitemid 36263279)
30. Nollen GJ, Groenink M, Tijssen JG, et al. Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J 2004;25:1146-52. (Pubitemid 38834072)
31. Watanabe S, Suzuki N, Kudo A, et al. Influence of aging on cardiac function examined by echocardiography. Tohoku J Exp Med 2005;207:13-19. (Pubitemid 41195354)
32. Alfakih K, Plein S, Thiele H, et al. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging 2003;17:323-9. (Pubitemid 36259246)
33. Sandstede J, Lipke C, Beer M, et al. Age- and gender-specific differences in left and right ventricular cardiac function and mass determined by cine magnetic resonance imaging. Eur Radiol 2000;10:438-42. (Pubitemid 30145755)
34. de Backer J. The expanding cardiovascular phenotype of Marfan syndrome. Eur J Echocardiogr 2009;10:213-15.
35. Vracko R, Thorning D, Frederickson RG. Spatial arrangements of microfibrils in myocardial scars: application of antibody to fibrillin. J Mol Cell Cardiol 1990;22:749-57. (Pubitemid 20276282)
36. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011;89:265-72.
37. Li RK, Li G, Mickle DA, et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997;96:874-81. (Pubitemid 27329622)
38. Detaint D, Aegerter P, Tubach F, et al. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis 2010;103:317-25.
39. Gambarin FI, Favalli V, Serio A, et al. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. J Cardiovasc Med (Hagerstown) 2009;10:354-62.
40. Lacro RV, Dietz HC, Wruck LM, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 2007;154:624-31. (Pubitemid 47429596)